Bridgeway Capital Management’s Albany Molecular Research Inc AMRI Stock Holding History

Bridgeway Capital Management’s Portfolio AMRI Stock Details AMRI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-21,028	Closed	-$425K	–	1570
2015 Q2	$425K	Sell	21,028 -11,700	-36%	-$226K	0.01%	1144
2015 Q1	$576K	Hold	32,728	–	–	0.01%	1029
2014 Q4	$533K	Hold	32,728	–	–	0.01%	1032
2014 Q3	$722K	Sell	32,728 -6,900	-17%	-$141K	0.02%	898
2014 Q2	$797K	Sell	39,628 -370,000	-90%	-$6.27M	0.02%	873
2014 Q1	$7.62M	Sell	409,628 -2,572	-0.6%	-$35.4K	0.22%	82
2013 Q4	$4.16M	Buy	412,200 +28,900	+8%	+$349K	0.13%	168
2013 Q3	$4.94M	Sell	383,300 -80,900	-17%	-$995K	0.17%	112
2013 Q2	$5.51M	Buy	+464,200	New	+$5.03M	0.22%	71

Other funds holding AMRI

VAM

Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

PIP

Permian Investment Partners Dallas, Texas $905M AUM 13.43% 1-Year Est. Return

OWP

Obermeyer Wealth Partners Aspen, Colorado $2.17B AUM 19.33% 1-Year Est. Return

VNIM

Vaughan Nelson Investment Management Houston, Texas $11.3B AUM 53% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

EWM

Evercore Wealth Management New York $6.36B AUM 20.35% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bridgeway Capital Management's AMRI Position: Q3 2015 in Review

Bridgeway Capital Management sold out of Albany Molecular Research Inc (AMRI) in Q3 2015, closing a stake of 21,028 shares — an estimated $425K sold.

Bridgeway Capital Management first reported a position in AMRI in Q2 2013 and held it in 9 quarters. The position peaked at $7.62M in Q1 2014. 143 funds tracked by Wall St. Rank hold AMRI as of Q3 2015.

Bridgeway Capital Management reported no remaining Albany Molecular Research Inc position as of Q3 2015 after selling out during the quarter.
Bridgeway Capital Management sold 21,028 Albany Molecular Research Inc shares in Q3 2015, an estimated $425K.
Bridgeway Capital Management first reported a position in Albany Molecular Research Inc in Q2 2013 and held it in 9 quarters.
Bridgeway Capital Management's Albany Molecular Research Inc position peaked at $7.62M in Q1 2014.
143 funds tracked by Wall St. Rank held Albany Molecular Research Inc as of Q3 2015.

Based on Bridgeway Capital Management's 13F filing for Q3 2015, filed 16 Nov 2015.